Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Beijing Hope Pharmaceutical Co. Ltd. operates in the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action. This action is assigned to 1 distinct examiner and is located within 1 distinct art unit.
STONEBRAKER, ALYSSA RAE is the busiest examiner for the portfolio, managing 1 pending office action. This single figure represents the total pending workload for the company. The prosecution environment is highly concentrated with only 1 distinct examiner and 1 distinct art unit involved. This streamlined interaction allows for a focused strategy when responding to the current matter.
The involvement of 1 distinct art unit suggests the technology is specialized. Practitioners should focus their strategy on the specific requirements of STONEBRAKER, ALYSSA RAE. The presence of 1 distinct examiner means there are no internal comparisons to be made regarding examiner behavior within this portfolio. Because there is only 1 pending office action, legal teams can dedicate their full attention to the specific procedural requirements of the assigned individual.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STONEBRAKER, ALYSSA RAE | 1 | 58.9% | +49.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18570945 | LINKER AND CONJUGATE THEREFOR | STONEBRAKER, ALYSSA RAE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18570945 | LINKER AND CONJUGATE THEREFOR | STONEBRAKER, ALYSSA RAE | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18570945 | LINKER AND CONJUGATE THEREFOR | STONEBRAKER, ALYSSA RAE | 1642 | §102§103§112 | Non-Final OA | — | Pending | Dec 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBeijing Hope Pharmaceutical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alyssa Rae Stonebraker has the most, with 1 of Beijing Hope Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
